BMY/JNJ/BAY: Milvexian moves ahead at ESC

The first factor XIa clinical efficacy for stroke prevention was presented at the European Society of cardiology in Barcelona yesterday for both Bristol’s milvexian and Bayer’s asundexian. While both trials missed their headline composite endpoint which combined symptomatic strokes with non-symptomatic brain scan changes, Bristol’s milvexian demonstrated a 30% lowering the risk of symptomatic stroke...